NCT03656705View on ClinicalTrials.gov

CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 29, 2018

Primary Completion Date

November 30, 2020

Study Completion Date

December 31, 2020

Conditions
Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

CCCR-NK92 cells

CCCR-NK92 cells will be administered intravenously over 1h. The starting dose of CCCR-NK92 cells will be 1×10e7-1×10e8,twice a week. The first evaluation of the efficacy after 3 weeks of treatment.

Trial Locations (1)

453000

The first Affiliated Hospital of Xinxiang Medical University, Xinxiang

All Listed Sponsors
lead

Xinxiang medical university

OTHER

NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter